Escherichia (e.g., Escherichia Coli, Etc.) Patents (Class 424/241.1)
-
Patent number: 10881731Abstract: The present invention relates to methods for inducing an immune response, in particular methods for adjuvanting the immune response to an antigen comprising the separate administration of a saponin and a TLR4 agonist.Type: GrantFiled: December 19, 2017Date of Patent: January 5, 2021Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Margherita Coccia, Arnauld Michel Didierlaurent
-
Patent number: 10876143Abstract: The present invention provides methods of synthesizing trehalose analogues; methods of detecting mycobacteria, and trehalose analogues.Type: GrantFiled: December 18, 2017Date of Patent: December 29, 2020Assignees: Central Michigan University, University of Maine SystemInventors: Benjamin M. Swarts, Peter Woodruff
-
Patent number: 10335477Abstract: The invention provides compositions and methods for preventing, treating and diagnosing infection by Salmonella enterica serovar typhi (S. typhi) and/or S. paratyphi, i.e., typhoid fever.Type: GrantFiled: May 20, 2014Date of Patent: July 2, 2019Assignee: YALE UNIVERSITYInventors: Jorge E. Galan, Jeongmin Song
-
Patent number: 9095539Abstract: The invention relates to an immunogenic composition and method of the immunogenic composition for the production and administration of a passive immunoprophylactic against enterotoxigenic Escherichia coli. The immunoprophylactic is made collecting anti-adhesin in the colostrum or milk of vaccinated domesticated animals such as cows. The immunoprophylactic is administered either as a dietary supplement or in capsular or tablet form.Type: GrantFiled: June 24, 2010Date of Patent: August 4, 2015Assignee: The United States of America as represented by the Secretary of the NavyInventor: Stephen J. Savarino
-
Patent number: 8992940Abstract: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside associated activity affects an allergic condition and/or a hypersensitivity condition.Type: GrantFiled: January 18, 2013Date of Patent: March 31, 2015Assignee: Trident Pharmaceuticals, Inc.Inventors: Neil Andrew Williams, Timothy Raymond Hirst, John Bienenstock
-
Patent number: 8980279Abstract: The invention provides methods of treating inflammation in a specific organ or tissue of an individual. The method involves determining whether the individual has previously been infected with at least one pathogen that is pathogenic in the specific organ or tissue; and administering to the individual an anti-inflammatory composition comprising antigenic determinants, the antigenic determinants selected or formulated so that together they are specific for the at least one pathogen. The pathogen may be an endogenous or exogenous pathogen, and may further be a bacterial pathogen, a viral pathogen, a fungal pathogen, a protozoan pathogen, or a helminth pathogen.Type: GrantFiled: July 27, 2012Date of Patent: March 17, 2015Assignee: Qu BiologicsInventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
-
Patent number: 8945587Abstract: The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure relates to genetic engineering of Gram-negative bacteria expressing different species of lipid A on their surface. In one embodiment, the present disclosure provides for an engineered strain of E. coli according to Table 1. In another embodiment, the present disclosure provides for a lipopolysaccharide purified from an engineered strain of E. coli according to Table 1.Type: GrantFiled: February 28, 2013Date of Patent: February 3, 2015Assignee: The Board of Regents of The University of Texas SystemInventors: M. Stephen Trent, Brittany Needham, David Giles, Marvin Whiteley
-
Patent number: 8926992Abstract: The invention provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N. meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The invention also provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N. meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred.Type: GrantFiled: May 14, 2003Date of Patent: January 6, 2015Assignees: Novartis AG, Universiteit LeidenInventors: Giuseppe Del Guidice, Barbara Baudner
-
Patent number: 8920814Abstract: The invention provides compositions and methods for preventing a metabolic disorder or bacterial infection in a subject, the composition comprising a bacterial endotoxin.Type: GrantFiled: June 7, 2007Date of Patent: December 30, 2014Assignee: The Governors of the University of AlbertaInventor: Burim N. Ametaj
-
Publication number: 20140322274Abstract: A method for treating an rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside GM-1 associated activity in an amount effective to treat the disease.Type: ApplicationFiled: December 10, 2013Publication date: October 30, 2014Inventors: Neil Andrew Williams, Timothy Raymond Hirst, Toufic Osman Nashar
-
Patent number: 8858930Abstract: The invention provides live, attenuated enterohemorrhagic Escherichia coli (EHEC) bacteria in which the Shiga toxin coding sequences are deleted to abolish Shiga toxin production and one or more of the nucleotide sequences for the bacterial adhesin protein intimin, the locus of enterocyte effacement encoded regulator, and the translocated intimin receptor are mutated to inactivate the activity of the encoded protein(s). This live, attenuated E. coli bacteria is used in a vaccine for reducing or inhibiting carriage and shedding of EHEC in cattle.Type: GrantFiled: October 26, 2005Date of Patent: October 14, 2014Assignees: The United States of America as Represented by the Department of Veteran AffairsInventors: Chengru Zhu, Edgar Boedeker
-
Patent number: 8846052Abstract: A bacterial toxin protein such as a Shiga toxin protein is efficiently produced using plant cells. The plant cells are transformed using a DNA construct containing DNA encoding a hybrid protein in which the bacterial toxin proteins such as the Shiga toxin proteins are tandemly linked through a peptide having the following characteristics (A) and (B) to produce the bacterial toxin protein in the plant cells: (A) a number of amino acids is 12 to 30; and (B) a content of proline is 20 to 35%.Type: GrantFiled: April 28, 2009Date of Patent: September 30, 2014Assignees: Idemitsu Kosan Co., Ltd., National University Corporation Nara Institute of Science and TechnologyInventors: Kazutoshi Sawada, Takeshi Matsui, Mayumi Yoshida, Nobuo Yoshida, Kyoko Yoshida
-
Patent number: 8846058Abstract: A chimeric Shiga toxoid according to the invention contains an enzymatically-inactivated StxA subunit and a native StxB subunit. This hybrid Shiga toxoid induces the production of broadly cross-reactive species of antibodies against Shiga toxin following immunization. The StxA subunit is modified so that it is enzymatically inactive. The invention thus encompasses the Shiga toxoid or fragments thereof and the nucleic acid sequence of the Shiga toxoid or fragments thereof. The invention further encompasses the production of a Shiga toxoid, the production of antibodies using the Shiga toxoid and methods of productions, and an immunogenic composition containing the Shiga toxoid.Type: GrantFiled: February 16, 2007Date of Patent: September 30, 2014Assignee: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.Inventors: Michael J. Smith, Alison D. O'Brien, Louise D. Teel, Angela R. Melton-Celsa
-
Patent number: 8815251Abstract: The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity.Type: GrantFiled: January 16, 2013Date of Patent: August 26, 2014Assignee: Allertein Therapeutics, LLCInventors: Michael J. Caplan, Howard B. Sosin, H. Kim Bottomly, A. Wesley Burks, Jr., Hugh A. Sampson
-
Patent number: 8734811Abstract: Compositions and methods for stimulating an immune response against Shiga toxin-producing Escherichia coli (STEC) antigens are disclosed. The compositions include a multiple epitope fusion protein comprising more than one epitope of an immunogenic STEC protein from more than one STEC serotype. Additional compositions include at least two purified STEC proteins, wherein the STEC proteins are selected from a full-length STEC protein, an immunogenic fragment or variant thereof, wherein at least one of the STEC proteins generates antibodies that react with STEC O157 and at least one other STEC serotype.Type: GrantFiled: April 6, 2010Date of Patent: May 27, 2014Assignee: University of SaskatchewanInventors: Andrew Potter, David Asper, Dragan Rogan
-
Patent number: 8673311Abstract: The present invention relates to a method of coating a spore with one or more therapeutic agents. The present invention also relates to a coated spore obtained by the method of the present invention and the use of the coated spore as a vaccine.Type: GrantFiled: September 21, 2010Date of Patent: March 18, 2014Assignee: Royal Holloway and Bedford New CollegeInventors: Simon Michael Cutting, Hong Anh Huynh
-
Publication number: 20140004178Abstract: The present disclosure relates to vaccine compositions and methods of using the vaccine compositions to provide protection against various Gram-negative bacterial infections, including Burkholderia infections.Type: ApplicationFiled: January 12, 2012Publication date: January 2, 2014Applicant: THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUNDInventor: Lisa A. Morici
-
Patent number: 8481026Abstract: Bacteria with improved survival under toxic and oxidative stress and methods of using the same for bioremediation are described. Many bacteria such as Escherichia coli have been found to naturally reduce toxic pollutants into a less toxic form, such as by reducing Chromium (VI) to Chromium (III). Reducing such toxins generates damaging reactive oxygen species, so it is important to find a defense for these bacteria against the associated oxidative stress. Trehalose is a small biomolecule that has been shown to protect bacteria from various types of stress by accumulating within the cells. The present invention is directed to bacteria genetically modified to overexpress trehalose biosynthesis genes. The bacteria demonstrate improved viability when challenged with toxins and oxidative stress. The present invention provides inexpensive and beneficial bacteria and methods for environmental remediation.Type: GrantFiled: April 16, 2010Date of Patent: July 9, 2013Inventors: Peter J. Woodruff, Tamlyn M. Frederick
-
Patent number: 8460648Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E.Coli, Gemmiger, Desullomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathoenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.Type: GrantFiled: July 25, 2001Date of Patent: June 11, 2013Inventor: Thomas Julius Borody
-
Patent number: 8440203Abstract: The present invention discloses methods for protecting newborn calves against neonatal diarrhea by vaccinating pregnant cows and/or pregnant heifers, while minimizing the number of separate occasions producers are required to assemble the cattle.Type: GrantFiled: November 6, 2009Date of Patent: May 14, 2013Assignee: Intervet Inc.Inventors: Terri L. Wasmoen, Huchappa Jayappa, Randall Gene Davis, Catherine M. Peters
-
Patent number: 8425917Abstract: The present invention describes the use of a mutant form of EtxB or CtxB to deliver an agent to a target cell wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB.Type: GrantFiled: April 30, 2008Date of Patent: April 23, 2013Assignee: Hunter Immunology LtdInventor: Timothy Raymond Hirst
-
Patent number: 8425916Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.Type: GrantFiled: April 21, 2011Date of Patent: April 23, 2013Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub
-
Patent number: 8357372Abstract: The use of an agent in the manufacture of a medicament to affect an allergic condition and/or a hypersensitivity condition is described. The agent is capable of modulating a ganglioside associated activity. The agent is not coupled to an antigen. The modulation of the ganglioside activity affects an allergic condition and/or a hypersensitivity condition.Type: GrantFiled: March 27, 2007Date of Patent: January 22, 2013Assignee: Trident Pharmaceuticals, Inc.Inventors: Neil Andrew Williams, Timothy Raymond Hirst, John Bienenstock
-
Patent number: 8357486Abstract: Described herein are methods for detecting a bacteria in a subject and methods for detecting, imaging or diagnosing a site, disease, disorder or condition in a subject using bacteria. The methods can be used in conjunction with methods for treating a disease, disorder or condition. Such sites, diseases and disorders include sites of cellular proliferation, such as tumors, tumor tissues, metastases, areas of inflammation, immunoprivileged sites or tissues, wounds and infections. Further described are bacteria for use in the methods and compositions, combinations and kits, including diagnostic and pharmaceutical compositions, containing a bacterium. Bacteria described herein include those that bind, sequester or accumulate radiolabeled compounds by expression of an endogenous gene product that binds to the radiolabeled compound. Additional imaging and therapeutic agents and methods also are described.Type: GrantFiled: January 9, 2009Date of Patent: January 22, 2013Assignee: Genelux CorporationInventors: Jochen Harald Stritzker, Aladar A. Szalay
-
Patent number: 8343509Abstract: Described herein are methods for detecting a bacteria in a subject and methods for detecting, imaging or diagnosing a site, disease, disorder or condition in a subject using bacteria. The methods can be used in conjunction with methods for treating a disease, disorder or condition. Such sites, diseases and disorders include sites of cellular proliferation, such as tumors, tumor tissues, metastases, areas of inflammation, immunoprivileged sites or tissues, wounds and infections. Further described are bacteria for use in the methods and compositions, combinations and kits, including diagnostic and pharmaceutical compositions, containing a bacterium. Bacteria described herein include those that bind, sequester or accumulate radiolabeled compounds by expression of an endogenous gene product that binds to the radiolabeled compound. Additional imaging and therapeutic agents and methods also are described.Type: GrantFiled: September 1, 2011Date of Patent: January 1, 2013Assignee: Genelux CorporationInventors: Jochen Harald Stritzker, Aladar A. Szalay
-
Patent number: 8323668Abstract: The present invention describes a novel mechanism of adhesion by flagellated Gram-negative bacteria such as enterotoxigenic Escherichia coli (ETEC), where the bacteria secretes a protein, EtpA which binds to the conserved region of the flagellin protein located at the tip of the flagella. The present invention also discloses that EtpA-mediated interaction and intestinal colonization require interaction with flagellin. Also disclosed herein is a vaccine composition that can be used for either active or passive immunization of mammals for the prevention or treatment of infections caused by flagellated Gram-negative bacteria.Type: GrantFiled: March 26, 2008Date of Patent: December 4, 2012Assignee: The University of Tennessee Research FoundationInventor: James M. Fleckenstein
-
Patent number: 8318148Abstract: The invention provides strains of bacteria, especially enterotoxigenic E. coli, attenuated by mutations in the genes encoding enterotoxins (LT, ST, EAST1) and optionally further attenuated by deletion of additional chromosomal genes. In addition the invention provides strains of attenuated bacteria expressing immunogenic but non-toxic variants of one or more of these enterotoxins. These bacteria are useful as a vaccine against diarrhoeal disease.Type: GrantFiled: March 28, 2011Date of Patent: November 27, 2012Assignee: Acambis Research LimitedInventors: Arthur Keith Turner, Judith Greenwood, Jonathan Clive Stephens, Juliet Claire Beavis, Michael James Darsley
-
Patent number: 8282941Abstract: The present invention provides compositions including siderophore receptor polypeptides from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.Type: GrantFiled: April 21, 2011Date of Patent: October 9, 2012Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub
-
Patent number: 8277821Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.Type: GrantFiled: April 21, 2011Date of Patent: October 2, 2012Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub
-
Patent number: 8263561Abstract: The present invention relates to a therapeutic composition comprising a pharmaceutically active agent and a diarrheagenic agent, wherein the diarrheagenic agent induces diarrhea to reduce the harmful or undesired side effects of the pharmaceutically active agent when the pharmaceutically active agent is ingested at a dose higher than the prescribed dose.Type: GrantFiled: June 16, 2006Date of Patent: September 11, 2012Assignee: Amana Pharmaceuticals Corp.Inventor: Mohammed Saeed
-
Publication number: 20120213821Abstract: The invention concerns a novel method for extracting endotoxins from bacteria, and the use of said method for preparing compositions comprising endotoxins or derivatives thereof designed for human or animal use (scientific, medical usage).Type: ApplicationFiled: February 8, 2012Publication date: August 23, 2012Applicant: UNIVERSITE PARIS SUD XIInventor: Martine CAROFF
-
Patent number: 8246945Abstract: The present invention provides methods and compositions for treating or preventing allergic reactions, particularly anaphylactic reactions. Methods of the present invention involve administering microorganisms to allergic subjects, where the microorganisms contain a recombinant version of the protein allergen. The recombinant version can be wild-type or may include mutations within IgE epitopes of the protein allergen. Preferably the compositions are administered rectally. Particularly preferred microorganisms are bacteria such as E. coli. Any allergen may be used in the inventive methods. Particularly preferred allergens are anaphylactic allergens including protein allergens found in foods, venoms, drugs and latex. The inventive compositions and methods are demonstrated in the treatment of peanut-induced anaphylaxis.Type: GrantFiled: October 2, 2009Date of Patent: August 21, 2012Assignees: University of Arkansas, Mount Sinai School of Medicine of New York University, Allertein Therapeutics, LLCInventors: Michael J. Caplan, H. Kim Bottomly, Howard B. Sosin, A. Wesley Burks, Hugh A. Sampson
-
Patent number: 8241608Abstract: A method for treating allergy with a pharmaceutical composition containing a detoxified E. coli heat-labile enterotoxin, and, optionally, an allergen.Type: GrantFiled: March 23, 2010Date of Patent: August 14, 2012Assignees: Development Center for Biotechnology, DCB-USA LLCInventors: Yu-Shen Hsu, Jiu-Yao Wang
-
Publication number: 20120201853Abstract: Provided is a use of a holotoxin to reduce endoplasmic reticulum-associated degradation (ERAD) of misfolded or abnormally folded proteins The holotoxin can thus be used in a method to treat diseases related to ERAD Examples of misfolded proteins that are degraded in the ER include the cystic fibrosis transmembrane conductance regulator (CFTR) delta F508 mutant protein, a misfolded mutant (G268V) of multi-drug resistance 1 (MDR1), and the glucocerebrosidase (GCC) enzyme in Gaucher's disease cells Examples of suitable holotoxins include ricin, shiga toxin, exotoxin A, plasmid-encoded toxin, cholera toxin, and verotoxin 1 (VT1) VT1 is also known as verotoxin A, shiga-like toxin 1, shiga-like toxin 1, or shiga toxin in type 1 A non-toxic inactive VT1 can also be used wherein crucial residues of the A subunit active site are mutated, for example, the mutations Y77S and E167QType: ApplicationFiled: August 27, 2010Publication date: August 9, 2012Inventor: Clifford Lingwood
-
Patent number: 8236522Abstract: The present invention relates to an extract from bacterial strains useful as a treatment for disorders such as digestive or urinary tract disorders, compositions comprising the extract, and processes of making the extract from media that do not pose a risk of prion diseases.Type: GrantFiled: March 5, 2008Date of Patent: August 7, 2012Assignee: OM PharmaInventors: Jacques Alain Bauer, Marco Salvagni, Jean-Pierre Leon Vigroux, Laetitia Chalvet, Carlo Chiavaroli
-
Patent number: 8178340Abstract: The present invention relates to human specific Escherichia coli strains.Type: GrantFiled: August 13, 2008Date of Patent: May 15, 2012Assignee: INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Olivier Clermont, Erick Denamur, Tony Le Gall, Olivier Tenaillon
-
Patent number: 8133496Abstract: The present invention relates to methods and compositions for treating urinary tract infections. In particular, the present invention relates to vaccines and immune modulators for treating urinary tract infections.Type: GrantFiled: March 2, 2011Date of Patent: March 13, 2012Assignee: The Regents of the University of MichiganInventor: Harry L. T. Mobley
-
Patent number: 8110197Abstract: This invention relates to a mutant E. coli heat-labile enterotoxin (LT) subunit A that can be used as an adjuvant. This subunit A mutant contains an amino acid substitution at a position corresponding to position 61 of a wild-type LT. An LT containing this mutated subunit A exhibits reduced toxicity compared to its wild type counterpart.Type: GrantFiled: July 18, 2007Date of Patent: February 7, 2012Assignee: Development Center for BiotechnologyInventors: Yu-Shen Hsu, Young-Sun Lin, Ta-Tung Yuan
-
Patent number: 8088394Abstract: This invention relates to a mutant E. coli heat-labile enterotoxin (LT) subunit A that can be used as an adjuvant. This subunit A mutant contains an amino acid substitution at a position corresponding to position 61 of a wild-type LT. An LT containing this mutated subunit A exhibits reduced toxicity compared to its wild type counterpart.Type: GrantFiled: May 15, 2008Date of Patent: January 3, 2012Assignee: Development Center for BiotechnologyInventors: Yu-Shen Hsu, Young-Sun Lin, Ta-Tung Yuan
-
Patent number: 8062644Abstract: Disclosed herein are various genes that can be included in immunogenic compositions specific for pathogenic E. coli strains. The genes are from uropathogenic strains but are absent from non-pathogenic strains, and their encoded proteins have cellular locations which render them accessible to the immune system.Type: GrantFiled: February 17, 2006Date of Patent: November 22, 2011Assignee: Novartis Vaccines & Diagnostics SRL.Inventors: Mariagrazia Pizza, Laura Serino, Francesco Berlanda Scorza, Danilo Gomes Moriel, Maria Rita Fontana
-
Publication number: 20110280908Abstract: The present invention provides compositions comprising modified bacterial toxins and methods for using the modified bacterial toxins for targeting particular cell populations and for treating diseases.Type: ApplicationFiled: April 15, 2011Publication date: November 17, 2011Applicants: Services, National Institutes of Health, Office of Technology TransferInventors: Stephen H. Leppla, Shi-Hui Liu, Thomas H. Bugge
-
Patent number: 8057805Abstract: A novel Edwardsiella ictaluri E-ict-VL33 strain, a vaccine derived from the novel Edwardsiella ictaluri E-ict-VL33 strain, especially in immersion form and oral form, and a method for protecting fishes from the infection of Edwardsiella ictaluri, especially catfish, the method including a primary immersion immunization using immersion vaccine, and after an appropriate period, boosting by oral vaccination, resulting in a strong and long-lasting immunity for fishes.Type: GrantFiled: July 29, 2010Date of Patent: November 15, 2011Assignee: Schweitzer Biotech Company Ltd.Inventors: Tsun-Yung Kuo, Hsu Chung Gabriel Chen
-
Publication number: 20110236424Abstract: A method for treating allergy with a pharmaceutical composition containing a detoxified E. coli heat-labile enterotoxin, and, optionally, an allergen.Type: ApplicationFiled: March 23, 2010Publication date: September 29, 2011Applicants: Development Center for Biotechnology, DCB-USA LLCInventors: Yu-Shen Hsu, Jiu-Yao Wang
-
Patent number: 7988978Abstract: An antigen composition for stimulating an immune response in an inoculated avian species to at least one intestinal pathogenic organism includes seven field strains of E. coli, Pseudomona aeruginosa, Aerobacter aerogenes, Salmonella enteritidis, Salmonella typhimurium, Salmonella agona, and Salmonella Kentucky. The antigen composition can be used alone or in combination with a Marek's Disease vaccine to reduce shedding of E. coli and/or Salmonella bacteria.Type: GrantFiled: June 4, 2010Date of Patent: August 2, 2011Assignee: Nutrional Health Institute Laboratories, LLCInventor: Konky Sotomayor
-
Publication number: 20110150923Abstract: The invention provides immunogenic compositions for mucosal delivery comprising capsular saccharides from at least two of serogroups A, C, W135 and Y of N. meningitidis. It is preferred that the capsular saccharides in the compositions of the invention are conjugated to carrier protein(s) and/or are oligosaccharides. Conjugated oligosaccharide antigens are particularly preferred. The invention also provides immunogenic compositions comprising (a) a capsular saccharide antigen from serogroup C of N. meningitidis, and (b) a chitosan adjuvant. The composition preferably comprises (c) one or more further antigens and/or (d) one or more further adjuvants. The compositions are particularly suitable for mucosal delivery, including intranasal delivery. The use of chitosan and/or detoxified ADP-ribosylating toxin adjuvants enhances anti-meningococcal mucosal immune responses and can shift the Th1/Th2 bias of the responses.Type: ApplicationFiled: February 28, 2011Publication date: June 23, 2011Inventors: Giuseppe Del Giudice, Barbara Baudner, Derek O'Hagan
-
Patent number: 7951361Abstract: A bacterial cell which expresses three or more coli surface (CS) antigens and methods of making such a cell. The cell is useful in making vaccines against diarrhea.Type: GrantFiled: September 11, 2002Date of Patent: May 31, 2011Assignee: Acambis Research LimitedInventors: Arthur Keith Turner, Judith Greenwood, Jonathan Clive Stephens, Juliet Claire Beavis, Michael James Darsley
-
Patent number: 7943150Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions, including inducing the production of antibody in an animal.Type: GrantFiled: April 11, 2008Date of Patent: May 17, 2011Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub
-
Patent number: 7943151Abstract: The present invention provides compositions including siderophore receptor polypeptides from gram negative microbes, and preferably, lipopolysaccharide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions, including inducing the production of antibody in an animal.Type: GrantFiled: February 26, 2009Date of Patent: May 17, 2011Assignee: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub
-
Patent number: 7943122Abstract: The invention provides strains of bacteria, especially enterotoxigenic E. coli, attenuated by mutations in the genes encoding enterotoxins (LT, ST, EAST1) and optionally further attenuated by deletion of additional chromosomal genes. In addition the invention provides strains of attenuated bacteria expressing immunogenic but non-toxic variants of one or more of these enterotoxins. These bacteria are useful as a vaccine against diarrhoeal disease.Type: GrantFiled: September 11, 2002Date of Patent: May 17, 2011Assignee: Acambis Research LimitedInventors: Arthur Keith Turner, Judith Greenwood, Jonathan Clive Stephens, Juliet Claire Beavis, Michael James Darsley
-
Patent number: 7923001Abstract: The present invention relates to methods and compositions for treating urinary tract infections. In particular, the present invention relates to vaccines and immune modulators for treating urinary tract infections.Type: GrantFiled: September 5, 2008Date of Patent: April 12, 2011Assignee: The Regents of the University of MichiganInventor: Harry L. T. Mobley